Appointment Strengthens RenovoRx’s C-Suite Leadership to Support Commercial Growth of RenovoCath®MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more t ...

Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-DeliveryMOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that new clinical data will be presented at the 202 ...

MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting has been accepted. The meeting will be held February 4–8, 2026 in Savannah, Georgia. Researchers including Christophe ...

Core Insights - RenovoRx, Inc. is experiencing commercial momentum with its RenovoCath device being integrated into U.S. cancer centers' oncology treatment programs, enhancing chemotherapy delivery near tumor sites [1][2][5] Group 1: Commercial Adoption - The number of active commercial cancer centers using RenovoCath has increased from five in September 2025 to nine, with notable additions including City of Hope Cancer Center and Moffitt Cancer Center [2] - RenovoRx generated approximately $900,000 in sales revenue through September 2025, indicating a positive trend in commercialization efforts [5][12] Group 2: Clinical Impact - The TAMP therapy platform, enabled by RenovoCath, is highlighted for its potential to improve treatment for difficult-to-treat tumors, such as locally advanced pancreatic cancer [3][10] - The ongoing Phase III TIGeR-PaC trial is evaluating the intra-arterial delivery of gemcitabine via RenovoCath for treating locally advanced pancreatic cancer [10][13] Group 3: Strategic Developments - RenovoRx has established a dedicated commercial team to enhance its go-to-market strategy, which has led to accelerating adoption of RenovoCath [6] - The company is focusing on lessons learned from 2025 to drive revenue growth in 2026, emphasizing physician demand and effective training initiatives [6] Group 4: Future Prospects - The company is exploring further revenue-generating activities and potential partnerships to meet anticipated demand for RenovoCath [12] - RenovoCath has received Orphan Drug Designation for pancreatic cancer, which could provide seven years of market exclusivity upon FDA approval [14]

Core Viewpoint - RenovoRx is making significant progress in its commercial and clinical programs, particularly with its FDA-cleared drug-delivery device, RenovoCath, and its ongoing clinical trials for targeted oncology therapies [1][3]. Commercial Progress - The demand for RenovoCath as a standalone targeted drug-delivery device is increasing, with adoption growing among both new and returning customers, including leading cancer centers [2][10]. - In December 2024, RenovoRx received its first commercial purchase orders for RenovoCath devices, with several customers initiating repeat orders [10]. Clinical Trials - The ongoing Phase III TIGeR-PaC clinical trial is evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in patients with locally advanced pancreatic cancer (LAPC) [3][7]. - RenovoRx is also supporting capital-efficient, investigator-initiated trials in borderline resectable and metastatic pancreatic cancer, which may enhance the clinical utility of the TAMP™ therapy platform [3]. Product Information - RenovoCath is designed for the isolation of blood flow and delivery of fluids to selected sites in the peripheral vascular system, and is indicated for temporary vessel occlusion in various applications [5][6]. - The combination product candidate (IAG) is currently under investigation and has not yet been approved for commercial sale, but has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].

Core Insights - New pharmacokinetic (PK) and pharmacodynamic data from a sub-study in the Phase III TIGeR-PaC trial supports the efficacy of RenovoRx's TAMP therapy platform for targeted drug delivery in treating locally advanced pancreatic cancer (LAPC) [1][2][4] Group 1: Clinical Data and Findings - The sub-study evaluated intra-arterial gemcitabine (IAG) using the TAMP platform, showing reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared to intravenous (IV) gemcitabine [3][5] - A direct correlation was found between increased metabolite levels and reduced CA 19-9, a biomarker for chemotherapy response, indicating potential for improved clinical outcomes [3][4] - The study involved 16 patients across six clinical sites, with 11 receiving TAMP and IAG, and five receiving IV gemcitabine, measuring systemic drug exposure and peak plasma concentrations [5] Group 2: Implications for Treatment - The findings suggest that TAMP and IAG may enhance local drug potency while minimizing side effects associated with standard chemotherapy, providing a transformative option for LAPC patients [4][9] - The TAMP therapy platform aims to deliver chemotherapy directly to the tumor site, potentially improving treatment efficiency and effectiveness [4][9] Group 3: Company Overview and Future Directions - RenovoRx is focused on developing targeted oncology therapies and has commercialized the RenovoCath device, which is FDA-cleared for drug delivery [9][10] - The company is actively commercializing its TAMP technology and has generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [10] - RenovoRx is also exploring further revenue-generating activities and expanding its customer base among high-volume cancer centers [10]

Core Insights - Healthcare and biotechnology stocks experienced significant movements in after-hours trading, with several companies showing strong gains despite limited news flow [1] Company Summaries - Novo Nordisk A/S (NVO) saw a notable increase of 9.48%, closing at $52.66, following FDA approval of its Wegovy pill, the first oral GLP-1 medicine for obesity in the U.S., which is also approved to reduce cardiovascular risks [2] - Neumora Therapeutics, Inc. (NMRA) advanced 16.02% to $2.10, indicating investor interest possibly driven by broader sector momentum or speculative trading, as there were no specific news updates [3] - BioRestorative Therapies, Inc. (BRTX) rose 6.90% to $1.24, with investors reacting to a prior announcement regarding an FDA Type B meeting to discuss a potential accelerated BLA pathway for its BRTX-100 program for chronic lumbar disc disease [4] - RenovoRx, Inc. (RNXT) added 4.44% to close at $0.94, with earlier news of an accepted abstract submission for the ASCO Gastrointestinal Cancers Symposium 2026 contributing to investor interest [5] - IDEAYA Biosciences, Inc. (IDYA) gained 6.49% to $37.81, following the full enrollment of 435 patients in its Phase 2/3 trial for darovasertib, with expected data reporting in Q1 2026 [6] - Healthcare Triangle, Inc. (HCTI) climbed 6.72% to $1.43, with a recent announcement of an Advance Agreement for acquiring AI-powered customer experience firms, enhancing its position in global AI-driven solutions [7] - Alphatec Holdings, Inc. (ATEC) posted a modest gain of 2.80%, rising to $21.28, benefiting from ongoing investor confidence in the spine surgery provider [8]

Core Insights - Several biotechnology and life sciences companies experienced significant gains in after-hours trading, indicating strong investor interest in recent clinical and corporate developments [1] Company Summaries - Kura Oncology, Inc. (KURA) saw its shares rise to $10.57, an increase of 7.42% (+0.73), likely due to positive investor sentiment following the announcement of new data from its KOMET-007 Phase 1a/1b trial, which showed a favorable safety profile and encouraging antileukemic activity for its treatment regimen in acute myeloid leukemia patients [2] - SOPHiA GENETICS SA (SOPH) closed after hours at $4.85, gaining 5.21% (+0.24), with continued investor interest stemming from its collaboration with Complete Genomics to co-market precision oncology testing solutions [3] - Elutia Inc. (ELUT) experienced modest gains, with shares rising to $0.6045, up 3.10% (+0.0182), reflecting steady investor interest in the micro-cap biotech sector [4] - RenovoRx, Inc. (RNXT) added 2.47% (+0.02) to close at $0.9530, with recent news of its abstract submission acceptance for the ASCO Gastrointestinal Cancers Symposium 2026, where it will present findings from its ongoing Phase III trial [5] - Kodiak Sciences Inc. (KOD) posted a notable gain, climbing to $27.41, up 5.42% (+1.41), following the successful closing of a public offering that generated approximately $184 million in gross proceeds [6] - Day One Biopharmaceuticals, Inc. (DAWN) rose to $9.55, gaining 3.35% (+0.31), continuing to attract investor attention focused on oncology innovation [7] - Quantum BioPharma Ltd. (QNTM) advanced to $9.23, up 3.82% (+0.34), following the closing of a non-brokered private placement that raised gross proceeds of $750 [8]

Core Insights - RenovoRx, Inc. has announced the acceptance of its abstract submission for the ASCO Gastrointestinal Cancers Symposium 2026, focusing on its innovative targeted oncology therapies and the RenovoCath drug-delivery device [1][4] Company Overview - RenovoRx is a life sciences company specializing in targeted oncology therapies and has developed the FDA-cleared RenovoCath device for drug delivery [7] - The company aims to address high unmet medical needs in cancer treatment through its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform [7] Clinical Trial Information - The ongoing Phase III TIGeR-PaC clinical trial evaluates the TAMP therapy platform for treating locally advanced pancreatic cancer (LAPC) [6][10] - A pharmacokinetic and pharmacodynamic sub-study will compare intra-arterial gemcitabine delivered via RenovoCath to standard intravenous chemotherapy [2][3] Presentation Details - The abstract presentation is scheduled for January 9, 2026, at the ASCO GI symposium in San Francisco, with specific time slots for the presentation [4][5] Financial Performance - In the first nine months of 2025, RenovoRx generated approximately $900,000 in revenue from RenovoCath sales, indicating early commercial traction [8] - The company is actively exploring additional revenue-generating activities to meet anticipated demand for its products [9]

Core Perspective - The company is focused on innovating cancer treatment by prioritizing patient well-being alongside tumor destruction, aiming to localize therapy for better outcomes [2]. Company Background and Progress - The company is making significant strides in both commercial and clinical aspects, laying a strong foundation for growth in 2026 [1][2]. - A two-pronged approach to market potential has been initiated, with the commercialization of their therapeutic solutions underway [3].